How effective is the treatment with Apelvis? What are the side effects?

Alpelisib (Alpelisib) is an innovative treatment drug for specific types of breast cancer. It is mainly targeted at adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, PIK3CA mutation, advanced or metastatic breast cancer. These patients, often after failure of endocrine therapy, may choose apelvis as a further treatment option after testing in an FDA-approved trial.

Regarding the therapeutic effect of Apelvis, judging from the existing clinical trials and practical applications, it has shown significant efficacy. When used in combination with fulvestrant, Apelvis can precisely interfere with the PI3K/AKT signaling pathway in breast cancer cells and inhibit the growth and spread of tumor cells. Clinical data show that patients treated with apelvis combined with fulvestrant have longer progression-free survival than patients treated with placebo combined with fulvestrant, which means that apelvis can reduce the risk of disease progression and buy more treatment time for patients.

However, any drug has its side effects, and Apelvis is no exception. During the use of Apelvis, patients may experience a series of adverse reactions, including nausea, vomiting, fatigue, change in food taste, loss of appetite, weight loss, dry skin, etc. Additionally, some patients may develop severe diarrhea, which may lead to dehydration and kidney problems. Therefore, when using Apelvis, patients need to pay close attention to their physical condition. Once symptoms of discomfort occur, they should promptly inform their doctor and take appropriate treatment measures.

In addition to the above-mentioned side effects, Apelvis may also cause some more serious complications, such as lung problems (such as shortness of breath, cough, chest pain), high blood sugar (such as thirst, increased urination), etc. Although the incidence of these complications is relatively low, patients still need to be cautious and monitor their health with regular physical exams.

In general, apelvis, as a new type of therapeutic drug, has shown significant efficacy in the treatment of breast cancer. However, patients also need to pay attention to possible side effects and complications during use and take appropriate measures to deal with them. Currently, Apelvis is not available in China, and patients need to purchase it from overseas. In overseas markets, the price of the original version in India is approximately RMB 5,000 per box, while the generic version of the Lucius version in Laos is relatively more affordable, priced at more than RMB 2,000 per box. Patients can choose a suitable version according to their own conditions.